NDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
6
Data completeness
7/8 — Comprehensive
AURYXIA (ferric citrate) by Ipsen is phosphate. Approved for hyperphosphatemia, iron deficiency anemia, end stage renal disease and 1 more indications. First approved in 2014.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AURYXIA (ferric citrate) is an oral tablet approved in 2014 for treating iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. The drug operates through a dual mechanism: it binds phosphate in the gastrointestinal tract to lower serum phosphate levels, while ferric iron is reduced to ferrous form and absorbed to replenish iron stores and support hemoglobin synthesis. AURYXIA represents a novel therapeutic approach that simultaneously addresses both hyperphosphatemia and iron deficiency, common complications in CKD populations.
$0.2BPart D
4.2 years to LOEMechanism of Action
phosphate. This compound is insoluble and is excreted in the stool. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum. Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric iron is reduced from the ferric…
Indications (4)
Worked on AURYXIA at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.